Lyndon Clinic, Hobs Meadow, Solihull, Birmingham B92 8RW, e-mail: renjujoseph{at}mail.com,
Sandwell Mental Health NHS & Social CareTrust, West Bromwich
|
|
|---|
The aims of this study were to describe the characteristics of substance misuse services prescribing methadone for maintenance treatment of opioid dependence and to determine the average daily doses of methadone prescribed across England. A postal questionnaire survey of all substance misuse treatment centres in England was carried out.
RESULTS
A total of 298 treatment centres were identified and contacted, 212 of which responded to the survey (response rate of 71%). Of these, 157 were prescribing methadone for maintenance treatment; the majority (71%) were community-based and 125 centres had doctors attached. The most common formulation of methadone prescription was oral methadone mixture (152 centres, 97%). The mean daily dose of methadone prescribed was 47 mg. Surprisingly, 37 (24%) of the respondents felt that methadone maintenance treatment should be time-limited and 21 teams (13%) stated that patients should receive only drug substitution and no psychosocial interventions.
CLINICAL IMPLICATIONS
There is currently a move among substance misuse services towards community-based treatment. In our survey, the mean daily dose of methadone prescribed was less than the dosage recommended by the Department of Health. This suggests that specialist addiction services are continuing to underprescribe heroin substitutes. The inadequate understanding of some of the respondents of the basic principles of methadone maintenance treatment also raises concerns, and highlights the need for further training and education.
|
|
|---|
Studies in the UK have shown that for patients on methadone maintenance, daily doses of over 50 mg are associated with lower rates of heroin use (Department of Health, 1996). Research has also found that patients on higher doses of methadone have better outcomes (Farrell et al, 1994). Community pharmacy surveys of methadone prescribing in the UK reveal that over 50% of patients receive doses lower than 50 mg (Strang & Sheridan, 1998, 2001). A recent survey of methadone prescribing at an inner-city drug service suggested that a significant minority of patients were on a sub-therapeutic dose (Dunn, 2003). These findings have led to concerns that opiate-dependent patients are being undertreated.
Despite several pharmacy surveys, nationwide studies based on gathering information from the treating team are few. An important limitation of such pharmacy surveys is that patients who receive two prescriptions for different formulations of methadone, such as ampoules and oral mixture, are counted twice. Also, patients on detoxification programmes, slow reduction regimes and methadone maintenance are grouped together in these studies, thus skewing the results to the left (Dunn, 2003).
The aims of our study were to describe the characteristics of methadone maintenance treatment services across England, to determine the mean daily doses of methadone prescribed in maintenance treatments, and to determine the views of teams on the prescribing patterns.
|
|
|---|
The questionnaire consisted of 18 questions, covering the following areas: the types of treatment services and medical staffing, methadone prescribing practices and the respondents views on methadone prescribing. Simple descriptive analysis (mean and percentage calculations) was carried out on the numerical data obtained.
|
|
|---|
Types of treatment service and medical staffing
The types of substance misuse treatment services that prescribed methadone
for maintenance treatment are given in
Table 1.
|
View this table: [in a new window] | Table 1. Treatment services prescribing methadone for maintenance in substance misuse |
A total of 125 centres (79.6%) had doctors attached to the team. In 32 centres (20.4%), the prescriptions were written by the local general practitioner (GP), who was not directly attached to the units. Forty-two (26.8%) treatment centres had one doctor, 50 (31.8%) had two doctors, 24 (15.3%) had three doctors and 9 (5.7%) had four doctors. In all, there were 68 consultant psychiatrists, 74 GPs, 78 staff and associate specialist doctors and 30 senior house officers. Altogether, 15 931 patients were attending the 157 treatment centres for methadone maintenance treatment and on average, 101 patients were attending each centre (range=2-1300).
Methadone prescribing practices
The most common formulation of methadone prescribed was the oral methadone
mixture, with 152 centres (97%) prescribing this. Thirty-three centres (21%)
prescribed methadone tablets and 18 centres (11.5%) prescribed injectable
preparations in addition to the methadone mixture.
The maximum dose of methadone prescribed for maintenance ranged from 9 to 325 mg, with a mean of 116 mg. The minimum dose ranged from 1 to 70 mg. The mean daily dose for each centre was 47 mg (range 9100). Seven centres (4%) used serum levels to adjust the optimal dose, although these were used infrequently. None of the other 150 centres checked the serum levels of methadone.
Respondents views on methadone prescribing
A total of 77 (49%) centres expressed the view that there should be a
maximum and a minimum dose of methadone that should be prescribed to an
opiate-dependent patient; 63 (40%) centres felt that methadone maintenance
treatment should be restricted to specialised services; 37 (24%) centres were
of the opinion that methadone maintenance ought to be time-limited, but the
majority disagreed with this; 21 centres (13%) felt that opiate-dependent
patients should receive only methadone, and no counselling or social
interventions.
|
|
|---|
In this survey, the proportion of services prescribing methadone tablets (21%) and methadone ampoules (11.5%) was higher than in other previous studies: the proportion of patients on methadone tablets in Dunns (2003) survey was 17.2% and that in Strang & Sheridans (1998) survey was 9.5%. This may be an indication that such preparations are available in many centres, but the actual number of patients prescribed them is low. Since drug formulation has no independent effect on illicit drug use, the choice could depend on availability and patient preferences. The Home Office (2000) document Reducing Drug Related Deaths, advises against the prescribing of controlled drugs to drug users because of the risk of injecting. It states that deaths would be reduced if agencies and GPs ceased to prescribe controlled drugs in tablet form or ampoules.
We found that the mean daily dose of methadone per patient, per centre was 47 mg, which is lower than the Department of Health (1996) recommendation of a daily dose of over 50 mg. This finding is consistent with the findings from previous studies conducted in the UK (Strang & Sheridan, 1998, 2001). International research shows that patients on higher doses of methadone show better outcomes (Ward et al, 1999). If lower doses mean poorer outcomes, the sub-optimal dose of methadone prescribing found in our survey is significant. Reasons remain unclear, although the fear of prescribing higher doses of methadone opiophobia and lack of urgency in changing the prescription style may be important contributory factors.
Very few treatment centres (4%) checked serum methadone levels as part of maintaining patients on methadone. It has been suggested that monitoring serum methadone levels is a much better way of determining the optimal dose of methadone than using arbitrary clinical judgement. Cost implications and resource limitations seem to be important practical considerations in this regard. Dunn (2003) argues that if its use were restricted only to patients who persistently use heroin on top of their prescribed methadone, the cost would be less prohibitive.
The view expressed by nearly half (49%) the services that there should be a maximum and minimum dose limit for prescribed methadone is remarkable, as many centres continue prescribing sub-therapeutic doses. A substantial proportion (24%) of centres in our survey felt that methadone maintenance should be time-limited. The opinion of 13% of services that patients should receive only methadone substitution and no psychosocial interventions requires further exploration. The benefits of offering methadone substitution as part of a psychosocial treatment package have been clearly demonstrated (Preston et al, 2000). Hence, our survey demonstrates that despite the commendable services offered by most teams, many require greater understanding of methadone maintenance treatment.
This national survey demonstrates that under-prescribing of methadone for methadone maintenance treatment is still prevalent in many substance misuse services across England. This, combined with an inadequate understanding of the underpinning principles of methadone maintenance treatment by a substantial minority of treatment services, points to a need for further training of professionals involved in treating opioid-dependent patients.
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||